Enhancing Immunotherapy Potential Through PD-L1 Upregulation—Combination of Anti-PD-L1 and mTOR Inhibitors Background Introduction In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly in the treatment of urothelial cancer (UC). PD-1/PD-L1 inhibitors restore T cell anti-tumor activity ...